Overview

Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)

Status:
Completed

Trial end date:
2019-10-10

Target enrollment:

Participant gender:

Summary

This is a clinical study where patients with diabetes and a vision threatening eye condition called "Diabetic Macular Edema" receive four injections into the eye at monthly intervals. The patients will already have tried the standard of care without complete success. The patients will be randomized to receive either a high dose, a low dose or a sham control treatment. The study will evaluate whether the new treatment improves vision and whether it changes the underlying course of the disease in the eye.

Phase:

Phase 2

Details

Lead Sponsor:

KalVista Pharmaceuticals, Ltd.

Treatments:

Endothelial Growth Factors
Kallikreins
Plasma Kallikrein